MSKCC | Strategic Alliance Partners

January 13, 2021

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

January 07, 2021

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

December 28, 2020

December 28, 2020 - The investigational selective estrogen receptor degrader SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms.

December 02, 2020

Mark G. Kris, MD, discusses the strengths of this year’s New York Lung Cancers Symposium, the advances that have been made over the past year, and potential routes forward in advancing the field of lung cancer.

November 17, 2020

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

November 04, 2020

The investigational small molecule, γ-secretase inhibitor AL101 monotherapy was found to elicit deep responses with a significant disease control rate in patients with recurrent or metastatic adenoid cystic carcinoma harboring NOTCH activating mutations.